Adherium Posts $2.1 Million Revenue and $14.16 Million Loss in FY2026
Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.
- Revenue surged 157% to $2.1 million driven by US RPM launch
- Net loss increased 12% to $14.16 million amid rising expenses
- Shift from R&D to commercialisation lowered development costs
- Cash position improved to $1.42 million from $43,255
- Completed 100:1 share consolidation and secured $1 million loan
Revenue Growth Fueled by US Remote Monitoring Expansion
Adherium Limited (ASX:ADR) posted a 157% jump in revenue to $2.1 million for the year ended 30 June 2026, propelled by the successful launch of its remote patient monitoring (RPM) program in the United States. This marks a significant pivot from its previous clinical trial focus to a subscription-based model delivering adherence and technique monitoring services.
Rising Losses Reflect Investment in Commercial Infrastructure
Despite revenue gains, Adherium's net loss widened 12% to $14.16 million, reflecting substantial investments in scaling its US operations. The company expanded its call centre, sales, and engineering teams and increased quality assurance efforts. Administrative expenses more than doubled to nearly $11.7 million, driven by higher payroll, contractor costs, capital raising activities, and executive recruitment. This surge partly stems from reclassifying employee costs following the closure of its New Zealand facility in March 2025.
Commercialisation Reduces R&D Spend as Focus Shifts
Research and development expenses declined to $2.08 million from $3.44 million the previous year, reflecting the transition away from clinical trials and product development toward commercialising the Hailie Smartinhaler platform. Similarly, sales and marketing costs dropped sharply to $1.8 million, indicating a more targeted approach to market entry.
Improved Liquidity and Capital Structure Moves
Adherium ended FY2026 with a cash balance of $1.42 million, a notable improvement from just $43,255 a year earlier, bolstered by capital raising and a $1 million loan at 12% interest from major shareholder Trudell Medical. The company also completed a 100:1 share consolidation, aiming to streamline its capital structure ahead of anticipated growth phases.
Auditor’s Going Concern Emphasis Highlights Funding Uncertainty
The financial statements are yet to be audited, with the independent auditor expected to include an emphasis of matter regarding the company's going concern status. This reflects ongoing uncertainty around securing sufficient funding until operations generate positive cash flows. Nonetheless, directors maintain that preparing accounts on a going concern basis remains appropriate.
Bottom Line?
Adherium’s FY2026 results highlight the growing pains of commercialising innovative health tech, with revenue momentum tempered by escalating costs and funding risks.
Questions in the middle?
- How will Adherium sustain growth while managing rising administrative expenses?
- What impact will the $1 million Trudell loan and share consolidation have on future capital raises?
- Can the US RPM subscription model scale quickly enough to reach cash flow breakeven?
